Quarterly ResultMay 13, 2026, 06:08 AM
Azitra Q1 2026 Net Loss $3.9M; Business & Pipeline Updates
AI Summary
Azitra, Inc. reported a net loss of $3.9 million for the first quarter of 2026, an increase from $3.1 million in the comparable period of 2025, with R&D and G&A expenses also rising. The company ended the quarter with $10.1 million in cash and cash equivalents. Operationally, Azitra made significant progress, including adding MD Anderson Cancer Center as a clinical site for its ATR-04 trial, launching new protein and peptide programs for cosmeceuticals, and securing a new U.S. patent for its lead product candidate, ATR-12. The company also priced a private placement financing of up to $10.5 million and expects key pipeline data in the second half of 2026.
Key Highlights
- Reported Q1 2026 net loss of $3.9 million, up from $3.1 million in Q1 2025.
- Research and Development expenses increased to $1.6 million in Q1 2026 from $1.3 million in Q1 2025.
- General and Administrative expenses rose to $2.4 million in Q1 2026 from $1.9 million in Q1 2025.
- Cash and cash equivalents stood at $10.1 million as of March 31, 2026.
- Secured private placement financing of up to $10.5 million, with potential for $20.9 million more from warrants.
- Added MD Anderson Cancer Center as a clinical site for the ATR-04 Phase 1/2 trial.
- Secured a new U.S. patent covering ATR-12 for Netherton syndrome.
- Anticipates topline data for ATR-12 and ATR-04 Phase 1/2 trials in H2 2026.